Jacobs Levy Equity Management, Inc C4 Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.18 - $6.03 $901,650 - $4.61 Million	-764,111 Reduced 88.39%	100,370 $567,000
Q3 2023 Nov 16, 2023	BUY	$1.81 - $3.89 $245,327 - $527,250	135,540 Added 18.59%	864,481 $1.61 Million
Q2 2023 Aug 14, 2023	BUY	$2.75 - $3.77 $14,410 - $19,754	5,240 Added 0.72%	728,941 $2 Million
Q1 2023 May 15, 2023	SELL	$3.1 - $9.02 $15,407 - $44,829	-4,970 Reduced 0.68%	723,701 $2.27 Million
Q4 2022 Feb 14, 2023	SELL	$5.42 - $10.24 $55,945 - $105,697	-10,322 Reduced 1.4%	728,671 $4.3 Million
Q3 2022 Nov 15, 2022	BUY	$8.03 - $12.77 $1.66 Million - $2.64 Million	206,573 Added 38.8%	738,993 $6.48 Million
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $2.69 Million - $14.1 Million	532,420 New	532,420 $4.01 Million
Q3 2021 Nov 15, 2021	SELL	$35.91 - $50.5 $840,760 - $1.18 Million	-23,413 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$30.39 - $42.18 $711,521 - $987,560	23,413 New	23,413 $886,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.